In just over a year, groups like AbbVie, Pfizer, AstraZeneca, J&J, Roche, Novartis, GSK or Lilly sign million-dollar investments to lower prices, production and R & D in exchange for exemptions. Read
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
In just over a year, groups like AbbVie, Pfizer, AstraZeneca, J&J, Roche, Novartis, GSK or Lilly sign million-dollar investments to lower prices, production and R & D in exchange for exemptions. Read